CARDINAL HEALTH INCCAH
ASignal's systematic analysis rates CAH as Neutral.
Reflects the latest available analysis · analyzed Oct 28, 2026
The case on CAH
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Positive free cash flow of $4.75B
- Revenue growth of 5.8% YoY
- Earnings growth of 68.8% YoY
- Low forward P/E of 17.50x indicating potential value
- RSI near neutral zone (58.99), not overbought
- Negative price momentum (-0.03)
- MACD below signal line, indicating weakening momentum
- Negative return on equity (implied by negative P/B ratio)
- Very low gross margin (3.84%)
- Weak current and quick ratios (0.88x and 0.42x)
- High dividend yield (84%) potentially unsustainable
Peers
Clustered with CAH by analysis-profile similarity.
See the full verdict on CAH
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CAH
Most investors never get a second opinion, let alone several. ASignal runs CAH past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.